Search results for "Prostate Cancer"
showing 10 items of 413 documents
Clinical implications ofCYP3Apolymorphisms
2006
Due to their enormous substrate spectrum CYP3A4, -3A5 and -3A7 constitute the most important drug-metabolising enzyme subfamily in humans. CYP3As are expressed predominantly, but not exclusively, in the liver and intestine, where they participate in the metabolism of 45 - 60% of currently used drugs and many other compounds such as steroids and carcinogens. CYP3A expression and activity vary interindividually due to a combination of genetic and nongenetic factors such as hormone and health status, and the impact of environmental stimuli. Over the past several years, genetic determinants have been identified for much of the variable expression of CYP3A5 and -3A7, but not for CYP3A4. Using th…
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
2004
Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…
IS VISCERAL ADIPOSITY INDEX (VAI)RELATED TO PROSTATE CANCER DETECTED BY BIOPSY?
2014
association between obesity and prostate cancer, yielding inconsistent results. Metabolic syndrome has been suggested to promote aggressive prostate tumors. In a previous study we failed to detect a relation between Body Mass Index (BMI) and prostate cancer Gleason score (1). BMI, although routinely adopted to measure obesity, has low sensitivity and specificity. A novel sex-specific obesity index, based on waist circumference (WC), BMI, triglycerides (TGs) and high density lipoproteins (HDL), the Visceral Adiposity Index (VAI), has been proposed to estimate the visceral adiposity dysfunction (2). The aim of our preliminary research was to correlate VAI and BMI with the presence of prostate…
DES-polyacetals as polymer therapeutics for the treatment of prostate cancer
2012
Esta tesis se centra en el diseño de nuevos conjugados polímero-fármaco sensibles a pH para usarse como agentes únicos o en terapia de combinación para el tratamiento del cáncer hormono-dependiente, en particular cáncer de próstata. Éstos conjugados se basan en sístemas poliacetalicos previamente descritos en los que el fármaco forma parte de la cadena principal del polímero. En el microambiente tumoral o después de la absorción celular por endocitosis, el descenso del pH encontrado en el compartimiento ácido del endosoma lisosomal, desencadena la degradación del polímero y como consecuencia la liberación del fármaco que se difunde fuera en el citosol. Para el diseño de éstos sistemas, la n…
Characterization of human γδ T cells infiltrating prostate cancer
ADIPONECTIN, LEPTIN AND MMP-3 PLASMATIC LEVELS CANNOT IDENTIFY HIGH-RISK PROSTATE CANCER IN PATIENTS UNDERGOING BIOPSY
2016
LYCOPENE AND PROSTATE CANCER: AN OVERVIEW
2018
Prostate cancer is one of the most common cancers in the world. Its pathogenesis is multifactorial and is linked to risk factors such as age, diet, cigarette smoking, family history and the onset of oxidative stress. In recent times, therefore, we are investigating the use of antioxidants as a primary and tertuary prevention of prostate cancer. Numerous studies in the literature focused on lycopene, a molecule belonging to the family of carotenoids that is commonly foud in tomatoes and products derived from it. The literature analyzed in the last two years shows how lycopene inhibits different mecchanism linked to carcinogenesis and tumor progression. However, there are still many points to…
Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.
2003
OBJECTIVE: To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS: From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2-4N0-3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS: Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an object…
Short and mid-term Functional Outcomes after High-intensity Ultrasound (HiFu) in the treatment of patients with localized advanced prostate cancer
2010
Vīriešu līdzestība prostatas vēža skrīningā
2019
Onkoloģisko slimību skaits ar katru gadu pieaug, tāpēc agrīnai diagnosticēšanai ir liela nozīme. Bakalaura darba tēma „Vīriešu līdzestība prostatas vēža skrīningā”. Pētījuma aktualitāti noteica statistiski apstiprināts fakts, ka prostatas vēzis ir viens no izplatītākajām onkoloģiskām slimībām Latvijā vīriešu vidū. Hipotēze: Vīriešu līdzestība prostatas vēža skrīningā būtiski ietekmē agrīnu slimības diagnosticēšanu. Darba mērķis: Noskaidrot vīriešu līdzestību prostatas vēža skrīninga programmas ietvaros. Pētījuma veikšanai izmantota kvantitatīvā pētniecības metode. Pētījuma instruments – anketa. Pētījuma rezultāti liecina, ka lielākā daļa respondentu (88%) izprot savlaicīgu diagnosticēšanas …